Prelude Therapeutics
PRLD
51 hedge funds and large institutions have $2.47B invested in Prelude Therapeutics in 2020 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 18 closing their positions.
147% more capital invested
Capital invested by funds: $1,000M → $2.47B (+$1.47B)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
67% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 18
31% more funds holding
Funds holding: 39 → 51 (+12)
0.82% more ownership
Funds ownership: 78.48% → 79.29% (+0.82%)
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$53.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$30.6M |
| 3 |
BlackRock
New York
|
+$28.6M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.53M |
| 5 |
State Street
Boston,
Massachusetts
|
+$7.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$11.6M |
| 2 |
UBS AM
Chicago,
Illinois
|
-$10.5M |
| 3 |
Millennium Management
New York
|
-$5.71M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$5.67M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$5.4M |
PRLD Hedge Fund Activity: Q4 2020 in Review
51 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q4 2020, worth a combined $2.47B — up 147% from $1,000M a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new PRLD positions and 18 closed out — a net gain of 12 holders — while 7 added to existing stakes and 7 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $53.8M. The largest seller was Massachusetts Financial Services, cutting an estimated $11.6M.
- 51 institutional investors held Prelude Therapeutics (PRLD) as of Q4 2020, up from 39 in Q3 2020.
- Funds reported $2.47B of Prelude Therapeutics stock for Q4 2020, up 147% quarter-over-quarter.
- 30 funds opened new Prelude Therapeutics positions in Q4 2020 and 18 closed out, a net change of +12 holders.
- The largest Prelude Therapeutics buyer in Q4 2020 was Fidelity Investments, an estimated $53.8M added.
- The largest Prelude Therapeutics seller in Q4 2020 was Massachusetts Financial Services, an estimated $11.6M sold.
Based on aggregated 13F filings for Q4 2020.